Our Response to COVID-19

As the COVID-19 pandemic unfolded, Brevitest recognized early on that its point-of-care diagnostic platform could play a meaningful role in curbing the health crisis by providing easy to use diagnostics that can widely deployed. We have developed a first-in-class diagnostic test for virus-specific IgA in saliva. The test is currently under review for an emergency use authorization (EUA) at the FDA.

 

We continue to work on development of other diagnostic tests to combat the pandemic. Check back for more updates.

A Painless way to test for COVID-19

Brevitest IgA Saliva Serology Test for SARS-CoV-2

The Brevitest IgA Saliva Serology Test for SARS-CoV-2 is an enzyme-linked immunoassay intended for the qualitative detection of IgA antibodies to SARS-CoV-2 in human saliva. The test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

The test is designed to be simple to administer and quick to run on Brevitest’s proprietary Acuity™ analyzers, with very little sample preparation.

*The test is not currently available for sale, pending FDA approval

The Brevitest Acuity™ analyzer

  • The Brevitest Acuity™ analyzer is a small, tabletop device that runs Brevitest immunoassays.
  • The small analyzer does not require any inputs beyond accepting the test cartridge. It then performs an entire laboratory-quality ELISA test on the test cartridge. At the end, the test data is uploaded to the cloud. And the analyzer is ready to run the next test.

Take A Look

For More Information

COVID-19 Tests
& Antibodies 101

Learn more about
Brevitest

Get in Touch
TODAY!

Do NOT follow this link or you will be banned from the site!